Avila Therapeutics

Avila Therapeutics is a biotechnology company focused on the development of covalent drugs to treat cancer and other autoimmune diseases.

Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.